Actively Recruiting
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Led by Recursion Pharmaceuticals Inc. · Updated on 2026-05-08
170
Participants Needed
6
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
CONDITIONS
Official Title
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
- Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
- Eastern cooperative oncology group (ECOG) performance status 641; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of 6470.
- Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
You will not qualify if you...
- Received treatment with another RBM39 degrader
- Clinically significant gastrointestinal (GI) or GI malabsorption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
3
SCRI Oncology Partners - PPDS
Nashville, Tennessee, United States, 37203
Withdrawn
4
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
5
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
6
McGill University Health Centre (MUHC) - The Montreal
Québec, Canada, H4A3J1
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here